SlideShare ist ein Scribd-Unternehmen logo
1 von 22
 
Serum Selenium Level and Prostate Cancer: A Case-Control Study   G.POURMAND, M.D. Professor of Urology, Urology Research Center, Medical Sciences/University of Tehran  Tehran, IRAN
Background  Essential trace element (1)      Meat, seafood, grains, eggs and etc (1)    Chemo-protective effects (2) 1- Combs GF Jr. 2004, Br J Cancer; Klein EA. 2004, J Urol; Platz EA and Helzlsouer KJ. 2001, Epidemiol Rev.  2- Redman C and Lee S. 1998, Cancer lett; Combs GF Jr. 2005, J Nutr; Kim YS and Milner J. 2001, Nutr Cancer.
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
   Various parts of the world        Other studies   ≠  Other reports
Objective Does selenium have any effect on  Prostate Cancer?
Materials and Methods ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Result  ,[object Object]
Comparison of demographic and baseline characteristics of patients in both groups;  (values are mean±SD)
Characteristic  Cancer  Group  (n=62) Control  Group  (n=68) P value  Age (yrs) 70.0±7.6 68.1±8.1 0.17 BMI (kg/m 2 ) 24.2±2.1 24.3±3.0 0.86 Se. Level (μg/L) 66.3±17.7 77.5±22.5 <0.002 FH of PCa 2(3.2%) 1(1.5%) 0.60 Smoking 0.46 Never 45(72.6%) 50(73.5%) Past  12(19.4%) 9(13.2%) Current  5(8.1%) 9(13.2%) PSA (ng/ml) 23.9±25.8 5.7±4.4 <0.001
Characteristic  Cancer  Group  (n=62) Control  Group  (n=68) P value  Tumor Grading  - Low (GS<7) 17(27.4%) - Intermediate (GS=7) 22(35.5%) - High (GS>7) 23(37.1%) - Treatment procedure   Surgery  24(38.7%) - Hormonal therapy  36(58.1%) - Radiotherapy  2(3.2%) - Nutritional selenium consumption  8.54±1.84 8.45±1.78 0.78
Association between age, BMI, smoking, serum selenium level and the risk of prostate cancer  Variable  OR  95%CI P value  Age (yrs) 1.037 0.99-1.09 0.134 BMI (kg/m2) 1.000 0.87-1.15 0.999 Smoking habit  Never  1 - - Former  0.935 0.34-2.26 0.896 Current  0.475 0.14-1.63 0.237 Selenium level (μg/L) <67.7 1 - - 67.7-89.29 0.478 0.21-1.10 0.084 ≥ 89.3 0.160 0.055-0.470 0.001
Correlation coefficients between serum selenium level and age, BMI, and PSA in controls group  Variable  Mean±SD Pearson r  P value  Age (yrs) 68.1±8.1 -0.19 0.12 BMI (kg/m 2 ) 24.3±3 -0.03 0.78 PSA (ng/ml) 5.75±4.4 0.03 0.83
 
Discussion ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 SELECT Trial     Plasma selenium decreases by aging     Role in progression     Smoking and selenium-prostate cancer association
Conclusion     Our study supports the hypothesis that selenium may protect prostate cancer      Supplementary selenium     Selenium-rich foods
Thank you for your time and attention

Weitere ähnliche Inhalte

Was ist angesagt?

Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancerMohamed Abdulla
 
Expanding treatment platform in m crc bayer - asyut 2018
Expanding treatment platform in m crc   bayer - asyut 2018Expanding treatment platform in m crc   bayer - asyut 2018
Expanding treatment platform in m crc bayer - asyut 2018Mohamed Abdulla
 
Liver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case PresentationLiver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case PresentationMohamed Abdulla
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storyMohamed Abdulla
 
Ueda2016 diabetes &amp; cancer - mesbah kamel
Ueda2016 diabetes &amp; cancer - mesbah kamelUeda2016 diabetes &amp; cancer - mesbah kamel
Ueda2016 diabetes &amp; cancer - mesbah kamelueda2015
 
Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...
Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...
Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...European School of Oncology
 
Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017Mohamed Abdulla
 
Nsclc slide deck
Nsclc slide deckNsclc slide deck
Nsclc slide deckPLMMedical
 
The Diabetes - Cancer Connection
The Diabetes - Cancer ConnectionThe Diabetes - Cancer Connection
The Diabetes - Cancer ConnectionSummit Health
 
ueda2012 diabetes and cancer-d.i.daskalova
ueda2012 diabetes and cancer-d.i.daskalovaueda2012 diabetes and cancer-d.i.daskalova
ueda2012 diabetes and cancer-d.i.daskalovaueda2015
 
Individualizing Therapy For Patients With Advanced Rcc
Individualizing Therapy For Patients With Advanced RccIndividualizing Therapy For Patients With Advanced Rcc
Individualizing Therapy For Patients With Advanced Rccfondas vakalis
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...isrodoy isr
 
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...European School of Oncology
 
Clasificación de riesgo en renal metastásico
Clasificación de riesgo en renal metastásicoClasificación de riesgo en renal metastásico
Clasificación de riesgo en renal metastásicoMauricio Lema
 
Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...
Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...
Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...Simba Takuva
 
Survivorship Issues Genetics 2016
Survivorship Issues Genetics 2016Survivorship Issues Genetics 2016
Survivorship Issues Genetics 2016OSUCCC - James
 

Was ist angesagt? (20)

Management of metastatic colorectal cancer
Management of metastatic colorectal cancerManagement of metastatic colorectal cancer
Management of metastatic colorectal cancer
 
Expanding treatment platform in m crc bayer - asyut 2018
Expanding treatment platform in m crc   bayer - asyut 2018Expanding treatment platform in m crc   bayer - asyut 2018
Expanding treatment platform in m crc bayer - asyut 2018
 
Liver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case PresentationLiver limited Metastatic Colorectal Cancer. Case Presentation
Liver limited Metastatic Colorectal Cancer. Case Presentation
 
metastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the storymetastatic colorectal cancer; a new chapter in the story
metastatic colorectal cancer; a new chapter in the story
 
Mc tiernan opac2013
Mc tiernan opac2013Mc tiernan opac2013
Mc tiernan opac2013
 
Ueda2016 diabetes &amp; cancer - mesbah kamel
Ueda2016 diabetes &amp; cancer - mesbah kamelUeda2016 diabetes &amp; cancer - mesbah kamel
Ueda2016 diabetes &amp; cancer - mesbah kamel
 
Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...
Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...
Gene Profiling in Clinical Oncology - Slide 5 - R. Labianca - What do we do t...
 
Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017Everything you need to know about moa of bone targeted agents amgen 2017
Everything you need to know about moa of bone targeted agents amgen 2017
 
Nsclc slide deck
Nsclc slide deckNsclc slide deck
Nsclc slide deck
 
Does Race Impact Postoperative Outcomes in Low Risk Prostate 10.23.08
Does Race Impact Postoperative Outcomes in Low Risk Prostate 10.23.08Does Race Impact Postoperative Outcomes in Low Risk Prostate 10.23.08
Does Race Impact Postoperative Outcomes in Low Risk Prostate 10.23.08
 
The Diabetes - Cancer Connection
The Diabetes - Cancer ConnectionThe Diabetes - Cancer Connection
The Diabetes - Cancer Connection
 
CRPC management
CRPC managementCRPC management
CRPC management
 
ueda2012 diabetes and cancer-d.i.daskalova
ueda2012 diabetes and cancer-d.i.daskalovaueda2012 diabetes and cancer-d.i.daskalova
ueda2012 diabetes and cancer-d.i.daskalova
 
Individualizing Therapy For Patients With Advanced Rcc
Individualizing Therapy For Patients With Advanced RccIndividualizing Therapy For Patients With Advanced Rcc
Individualizing Therapy For Patients With Advanced Rcc
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
 
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
Gene Profiling in Clinical Oncology - Slide 2 - T. Le Chevalier - Treatment o...
 
G. Ceresoli - Lung cancer - State of the art
G. Ceresoli - Lung cancer - State of the artG. Ceresoli - Lung cancer - State of the art
G. Ceresoli - Lung cancer - State of the art
 
Clasificación de riesgo en renal metastásico
Clasificación de riesgo en renal metastásicoClasificación de riesgo en renal metastásico
Clasificación de riesgo en renal metastásico
 
Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...
Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...
Simbarashe Takuva, AIDS 2010. Durability of first line antiretroviral therapy...
 
Survivorship Issues Genetics 2016
Survivorship Issues Genetics 2016Survivorship Issues Genetics 2016
Survivorship Issues Genetics 2016
 

Andere mochten auch

Andere mochten auch (7)

Nicb Research Overview
Nicb Research OverviewNicb Research Overview
Nicb Research Overview
 
Minerals 2
Minerals 2Minerals 2
Minerals 2
 
Nutrition12
Nutrition12Nutrition12
Nutrition12
 
Selenium compounds boost immune system to fight against cancer
Selenium compounds boost immune system to fight against cancerSelenium compounds boost immune system to fight against cancer
Selenium compounds boost immune system to fight against cancer
 
selenium
seleniumselenium
selenium
 
Trace elements and dental health
Trace elements and dental healthTrace elements and dental health
Trace elements and dental health
 
Antioxidants and their therapeutic implications
Antioxidants and their therapeutic implicationsAntioxidants and their therapeutic implications
Antioxidants and their therapeutic implications
 

Ähnlich wie Selenium

Treatment of Platinum sensitive relapsed carcinoma ovary
Treatment of Platinum sensitive relapsed carcinoma ovaryTreatment of Platinum sensitive relapsed carcinoma ovary
Treatment of Platinum sensitive relapsed carcinoma ovaryAlok Gupta
 
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016Mohamed Abdulla
 
Estudio Paramount cáncer de pulmón 2014
Estudio Paramount cáncer de pulmón 2014Estudio Paramount cáncer de pulmón 2014
Estudio Paramount cáncer de pulmón 2014Martín Lázaro
 
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...European School of Oncology
 
Renal Cell Carcinoma A New Standard Of Care
Renal Cell Carcinoma A New Standard Of CareRenal Cell Carcinoma A New Standard Of Care
Renal Cell Carcinoma A New Standard Of Carefondas vakalis
 
Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015Mohamed Abdulla
 
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptxINMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptxResidenteOncologiaMd
 
Prostate cancer nemrock 2015 sanofi
Prostate cancer nemrock 2015   sanofiProstate cancer nemrock 2015   sanofi
Prostate cancer nemrock 2015 sanofiMohamed Abdulla
 
Gastrointestinal-Pancreatic NET management
Gastrointestinal-Pancreatic NET managementGastrointestinal-Pancreatic NET management
Gastrointestinal-Pancreatic NET managementChandan K Das
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?Mohamed Abdulla
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Capacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCC
Capacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCCCapacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCC
Capacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCCMauricio Lema
 
Continuous Update Project and Systematic Literature Reviews (Conference: Diet...
Continuous Update Project and Systematic Literature Reviews (Conference: Diet...Continuous Update Project and Systematic Literature Reviews (Conference: Diet...
Continuous Update Project and Systematic Literature Reviews (Conference: Diet...World Cancer Research Fund International
 
Management of colorectal cancer
Management of colorectal cancer Management of colorectal cancer
Management of colorectal cancer Mohamed Abdulla
 

Ähnlich wie Selenium (20)

Treatment of Platinum sensitive relapsed carcinoma ovary
Treatment of Platinum sensitive relapsed carcinoma ovaryTreatment of Platinum sensitive relapsed carcinoma ovary
Treatment of Platinum sensitive relapsed carcinoma ovary
 
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016Beyond lhrh analogues in hormone refractory prostate cancer   amman - 2016
Beyond lhrh analogues in hormone refractory prostate cancer amman - 2016
 
Estudio Paramount cáncer de pulmón 2014
Estudio Paramount cáncer de pulmón 2014Estudio Paramount cáncer de pulmón 2014
Estudio Paramount cáncer de pulmón 2014
 
2 predicting response to adt msk.eso 4.3.2011
2 predicting response to adt msk.eso 4.3.20112 predicting response to adt msk.eso 4.3.2011
2 predicting response to adt msk.eso 4.3.2011
 
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
NY Prostate Cancer Conference - M.H. Hussain - Session 5: Predicting response...
 
Renal Cell Carcinoma A New Standard Of Care
Renal Cell Carcinoma A New Standard Of CareRenal Cell Carcinoma A New Standard Of Care
Renal Cell Carcinoma A New Standard Of Care
 
Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015Neuroendocrine tumors in 2015
Neuroendocrine tumors in 2015
 
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptxINMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
INMUNOTERPAPIA EN CANCER DE VIAS BILIARES AVANZADO.pptx
 
Management of crpc
Management of crpcManagement of crpc
Management of crpc
 
7 capdevila
7 capdevila7 capdevila
7 capdevila
 
HCC20121001
HCC20121001 HCC20121001
HCC20121001
 
Prostate cancer nemrock 2015 sanofi
Prostate cancer nemrock 2015   sanofiProstate cancer nemrock 2015   sanofi
Prostate cancer nemrock 2015 sanofi
 
Gastrointestinal-Pancreatic NET management
Gastrointestinal-Pancreatic NET managementGastrointestinal-Pancreatic NET management
Gastrointestinal-Pancreatic NET management
 
Prostate 101
Prostate 101Prostate 101
Prostate 101
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Capacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCC
Capacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCCCapacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCC
Capacitación fuerza de ventas BMS Nivo/Ipi 1ra línea RCC
 
Continuous Update Project and Systematic Literature Reviews (Conference: Diet...
Continuous Update Project and Systematic Literature Reviews (Conference: Diet...Continuous Update Project and Systematic Literature Reviews (Conference: Diet...
Continuous Update Project and Systematic Literature Reviews (Conference: Diet...
 
Management of colorectal cancer
Management of colorectal cancer Management of colorectal cancer
Management of colorectal cancer
 
Asco-cim.linfoma.pptx
Asco-cim.linfoma.pptxAsco-cim.linfoma.pptx
Asco-cim.linfoma.pptx
 

Mehr von Patricia Khashayar (20)

Natural remedies treat chronic wounds
Natural remedies treat chronic woundsNatural remedies treat chronic wounds
Natural remedies treat chronic wounds
 
Recommended food for Ramadan
Recommended food for RamadanRecommended food for Ramadan
Recommended food for Ramadan
 
sterile water
sterile watersterile water
sterile water
 
plastic surgeon
plastic surgeonplastic surgeon
plastic surgeon
 
Alternative medicine Coconut
Alternative medicine CoconutAlternative medicine Coconut
Alternative medicine Coconut
 
War-related health problems in Iraq
War-related health problems in IraqWar-related health problems in Iraq
War-related health problems in Iraq
 
Alternative medicine Carrot
Alternative medicine CarrotAlternative medicine Carrot
Alternative medicine Carrot
 
Alternative medicine Apple
Alternative medicine AppleAlternative medicine Apple
Alternative medicine Apple
 
infertility2
infertility2infertility2
infertility2
 
Alternative medicine Cinnamon
Alternative medicine CinnamonAlternative medicine Cinnamon
Alternative medicine Cinnamon
 
alternative medicine borage
alternative medicine boragealternative medicine borage
alternative medicine borage
 
Nanotalk last
Nanotalk lastNanotalk last
Nanotalk last
 
Shakibaei takes his final bow
Shakibaei takes his final bowShakibaei takes his final bow
Shakibaei takes his final bow
 
Alternative medicine Pomgrenate
Alternative medicine PomgrenateAlternative medicine Pomgrenate
Alternative medicine Pomgrenate
 
JC
JCJC
JC
 
Kaposi sarcoma
Kaposi sarcomaKaposi sarcoma
Kaposi sarcoma
 
A revolution in Chinese stem cell technology
A revolution in Chinese stem cell technologyA revolution in Chinese stem cell technology
A revolution in Chinese stem cell technology
 
Gabapentine
GabapentineGabapentine
Gabapentine
 
computer
computercomputer
computer
 
Alternative medicine Caraway
Alternative medicine CarawayAlternative medicine Caraway
Alternative medicine Caraway
 

Kürzlich hochgeladen

A Framework for Development in the AI Age
A Framework for Development in the AI AgeA Framework for Development in the AI Age
A Framework for Development in the AI AgeCprime
 
Sample pptx for embedding into website for demo
Sample pptx for embedding into website for demoSample pptx for embedding into website for demo
Sample pptx for embedding into website for demoHarshalMandlekar2
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024Lonnie McRorey
 
How to write a Business Continuity Plan
How to write a Business Continuity PlanHow to write a Business Continuity Plan
How to write a Business Continuity PlanDatabarracks
 
Generative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfGenerative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfIngrid Airi González
 
Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024Hiroshi SHIBATA
 
A Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software DevelopersA Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software DevelopersNicole Novielli
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteDianaGray10
 
DevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsDevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsSergiu Bodiu
 
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxThe Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxLoriGlavin3
 
Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...Farhan Tariq
 
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...panagenda
 
How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.Curtis Poe
 
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...Scott Andery
 
Generative AI for Technical Writer or Information Developers
Generative AI for Technical Writer or Information DevelopersGenerative AI for Technical Writer or Information Developers
Generative AI for Technical Writer or Information DevelopersRaghuram Pandurangan
 
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality AssuranceInflectra
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc
 
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Mark Goldstein
 
Emixa Mendix Meetup 11 April 2024 about Mendix Native development
Emixa Mendix Meetup 11 April 2024 about Mendix Native developmentEmixa Mendix Meetup 11 April 2024 about Mendix Native development
Emixa Mendix Meetup 11 April 2024 about Mendix Native developmentPim van der Noll
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxLoriGlavin3
 

Kürzlich hochgeladen (20)

A Framework for Development in the AI Age
A Framework for Development in the AI AgeA Framework for Development in the AI Age
A Framework for Development in the AI Age
 
Sample pptx for embedding into website for demo
Sample pptx for embedding into website for demoSample pptx for embedding into website for demo
Sample pptx for embedding into website for demo
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024
 
How to write a Business Continuity Plan
How to write a Business Continuity PlanHow to write a Business Continuity Plan
How to write a Business Continuity Plan
 
Generative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfGenerative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdf
 
Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024
 
A Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software DevelopersA Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software Developers
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test Suite
 
DevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsDevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platforms
 
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxThe Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
 
Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...
 
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
 
How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.
 
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
 
Generative AI for Technical Writer or Information Developers
Generative AI for Technical Writer or Information DevelopersGenerative AI for Technical Writer or Information Developers
Generative AI for Technical Writer or Information Developers
 
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
 
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
 
Emixa Mendix Meetup 11 April 2024 about Mendix Native development
Emixa Mendix Meetup 11 April 2024 about Mendix Native developmentEmixa Mendix Meetup 11 April 2024 about Mendix Native development
Emixa Mendix Meetup 11 April 2024 about Mendix Native development
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
 

Selenium

  • 1.  
  • 2. Serum Selenium Level and Prostate Cancer: A Case-Control Study G.POURMAND, M.D. Professor of Urology, Urology Research Center, Medical Sciences/University of Tehran Tehran, IRAN
  • 3. Background  Essential trace element (1)  Meat, seafood, grains, eggs and etc (1)  Chemo-protective effects (2) 1- Combs GF Jr. 2004, Br J Cancer; Klein EA. 2004, J Urol; Platz EA and Helzlsouer KJ. 2001, Epidemiol Rev. 2- Redman C and Lee S. 1998, Cancer lett; Combs GF Jr. 2005, J Nutr; Kim YS and Milner J. 2001, Nutr Cancer.
  • 4.
  • 5. Various parts of the world   Other studies  ≠ Other reports
  • 6. Objective Does selenium have any effect on Prostate Cancer?
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12. Comparison of demographic and baseline characteristics of patients in both groups; (values are mean±SD)
  • 13. Characteristic Cancer Group (n=62) Control Group (n=68) P value Age (yrs) 70.0±7.6 68.1±8.1 0.17 BMI (kg/m 2 ) 24.2±2.1 24.3±3.0 0.86 Se. Level (μg/L) 66.3±17.7 77.5±22.5 <0.002 FH of PCa 2(3.2%) 1(1.5%) 0.60 Smoking 0.46 Never 45(72.6%) 50(73.5%) Past 12(19.4%) 9(13.2%) Current 5(8.1%) 9(13.2%) PSA (ng/ml) 23.9±25.8 5.7±4.4 <0.001
  • 14. Characteristic Cancer Group (n=62) Control Group (n=68) P value Tumor Grading - Low (GS<7) 17(27.4%) - Intermediate (GS=7) 22(35.5%) - High (GS>7) 23(37.1%) - Treatment procedure Surgery 24(38.7%) - Hormonal therapy 36(58.1%) - Radiotherapy 2(3.2%) - Nutritional selenium consumption 8.54±1.84 8.45±1.78 0.78
  • 15. Association between age, BMI, smoking, serum selenium level and the risk of prostate cancer Variable OR 95%CI P value Age (yrs) 1.037 0.99-1.09 0.134 BMI (kg/m2) 1.000 0.87-1.15 0.999 Smoking habit Never 1 - - Former 0.935 0.34-2.26 0.896 Current 0.475 0.14-1.63 0.237 Selenium level (μg/L) <67.7 1 - - 67.7-89.29 0.478 0.21-1.10 0.084 ≥ 89.3 0.160 0.055-0.470 0.001
  • 16. Correlation coefficients between serum selenium level and age, BMI, and PSA in controls group Variable Mean±SD Pearson r P value Age (yrs) 68.1±8.1 -0.19 0.12 BMI (kg/m 2 ) 24.3±3 -0.03 0.78 PSA (ng/ml) 5.75±4.4 0.03 0.83
  • 17.  
  • 18.
  • 19.
  • 20.  SELECT Trial  Plasma selenium decreases by aging  Role in progression  Smoking and selenium-prostate cancer association
  • 21. Conclusion  Our study supports the hypothesis that selenium may protect prostate cancer  Supplementary selenium  Selenium-rich foods
  • 22. Thank you for your time and attention